Evogliptin hydrochloride
Based on 2 publication(s) in Google Scholar
Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1246960-27-9
- Formule: C19H27ClF3N3O3
- Masse moléculaire:437.88
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Evogliptin hydrochloride
More
Activité biologique
Description
Chemical Information
-
CAS No. 1246960-27-9
-
Masse moléculaire 437.88
-
Formule C19H27ClF3N3O3
-
SMILES
O=C1NCCN([C@@H]1COC(C)(C)C)C(C[C@@H](CC2=CC(F)=C(C=C2F)F)N)=O.Cl
-
Synonyms
DA-1229 hydrochloride
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
Aortic valve stenosis serum IGFBP2 mediates female-specific Evogliptin resistance in valve myofibroblasts. [Abstract]2026 Jul 13;45(7):117678. PMID: 42441401 -
bioRxiv
Circulating biomarkers in serum from aortic valve stenosis patients predict sex-specific drug responses in valve myofibroblasts. [Abstract]2026 Jan 20:2026.01.16.700010. PMID: 41648356
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)